Patents by Inventor Douglas P. Cerretti
Douglas P. Cerretti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7695948Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.Type: GrantFiled: February 21, 2007Date of Patent: April 13, 2010Assignee: Immunex CorporationInventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
-
Patent number: 7399832Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: December 19, 2006Date of Patent: July 15, 2008Assignee: Immunex CorporationInventor: Douglas P. Cerretti
-
Publication number: 20080160571Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.Type: ApplicationFiled: February 21, 2007Publication date: July 3, 2008Applicant: Immunex CorporationInventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
-
Patent number: 7217553Abstract: The disclosure provides purified and isolated SVPH1–8 polypeptides, nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against such polypeptide, and fragmented peptides derived from these polypeptide. In addition, the disclosure provides uses of such polypeptides, fragmented peptides, antibodies and nucleic acids as well as kits containing the foregoing.Type: GrantFiled: October 3, 2002Date of Patent: May 15, 2007Assignee: Immunex CorporationInventor: Douglas P. Cerretti
-
Patent number: 7199224Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.Type: GrantFiled: April 25, 2003Date of Patent: April 3, 2007Assignee: Immunex CorporationInventors: Roy A Black, Charles Rauch, Carl J March, Douglas P Cerretti
-
Patent number: 7196168Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: July 23, 2002Date of Patent: March 27, 2007Assignee: Immunex CorporationInventor: Douglas P Cerretti
-
Patent number: 7074408Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.Type: GrantFiled: February 23, 2001Date of Patent: July 11, 2006Assignee: Immunex CorporationInventors: William C. Fanslow, III, Douglas P. Cerretti, Kurt M. Poindexter, Roy A. Black
-
Patent number: 7067475Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.Type: GrantFiled: February 3, 2003Date of Patent: June 27, 2006Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Luis G. Borges, William C. Fanslow, III
-
Patent number: 6949366Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.Type: GrantFiled: July 12, 2001Date of Patent: September 27, 2005Assignee: Amgen Inc.Inventors: M. Patricia Beckmann, Douglas P. Cerretti
-
Patent number: 6787644Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: August 7, 2000Date of Patent: September 7, 2004Assignee: Immunex Corp.Inventor: Douglas P. Cerretti
-
Publication number: 20040038364Abstract: The invention is directed to purified and isolated novel SVPH polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, and the uses of the above.Type: ApplicationFiled: September 19, 2003Publication date: February 26, 2004Applicant: Immunex CorporationInventor: Douglas P. Cerretti
-
Publication number: 20030175816Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.Type: ApplicationFiled: April 25, 2003Publication date: September 18, 2003Applicant: Immunex CorporationInventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
-
Publication number: 20030162712Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.Type: ApplicationFiled: February 3, 2003Publication date: August 28, 2003Applicant: Immunex CorporationInventors: Douglas P. Cerretti, Luis G. Borges, William C. Fanslow
-
Patent number: 6596852Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.Type: GrantFiled: October 15, 2001Date of Patent: July 22, 2003Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Pranhitha Reddy
-
Publication number: 20030100091Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: ApplicationFiled: July 23, 2002Publication date: May 29, 2003Applicant: Immunex CorporationInventor: Douglas P. Cerretti
-
Publication number: 20030082771Abstract: The disclosure provides purified and isolated SVPH1-8 polypeptides, nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against such polypeptide, and fragmented peptides derived from these polypeptide. In addition, the disclosure provides uses of such polypeptides, fragmented peptides, antibodies and nucleic acids as well as kits containing the foregoing.Type: ApplicationFiled: October 3, 2002Publication date: May 1, 2003Applicant: Immunex CorporationInventor: Douglas P. Cerretti
-
Patent number: 6555354Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.Type: GrantFiled: November 29, 2000Date of Patent: April 29, 2003Assignee: Immunex CorporationInventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
-
Patent number: 6521424Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization. Also provided are materials and methods for recombinant expression of Tek antagonists.Type: GrantFiled: December 7, 2000Date of Patent: February 18, 2003Assignee: Immunex CorporationInventors: Douglas P. Cerretti, William C. Fanslow, III
-
Patent number: 6492140Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.Type: GrantFiled: January 3, 2001Date of Patent: December 10, 2002Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Pranhitha Reddy
-
Patent number: 6485956Abstract: The disclosure provides purified and isolated SVPH1-8 polypeptides, nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against such polypeptide, and fragmented peptides derived from these polypeptide. In addition, the disclosure provides uses of such polypeptides, fragmented peptides, antibodies and nucleic acids as well as kits containing the foregoing.Type: GrantFiled: July 14, 2000Date of Patent: November 26, 2002Assignee: Immunex CorporationInventor: Douglas P. Cerretti
